Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck

Basit Öğe Kaydı
dc.authorid0000-0002-0077-6971
dc.contributor.authorSezgin Göksu, Sema
dc.contributor.authorTatlı, Ali Murat
dc.contributor.authorGeredeli, Çağlayan
dc.contributor.authorAtçı, Mustafa
dc.contributor.authorBeşen, Ali Ayberk
dc.contributor.authorMertsoylu, Hüseyin
dc.contributor.authorUysal, Mükremin
dc.contributor.authorÖzdoğan, Mustafa
dc.contributor.authorGöktaş Aydın, Sabin
dc.contributor.authorBilici, Ahmet
dc.contributor.authorKaraağaç, Mustafa
dc.contributor.authorArtaç, Mehmet
dc.contributor.authorKaplan, Muhammet Ali
dc.contributor.authorEbinç, Senar
dc.contributor.authorCoşkun, Hasan Şenol
dc.date.accessioned2021-10-26T08:18:15Z
dc.date.available2021-10-26T08:18:15Z
dc.date.issued2021
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractPurpose In this study, we looked for whether treatment-induced rash predicts treatment efficacy in patients with recurrent/metastatic HNSCC treated with Cetuximab and chemotherapy. Methods Patients who were treated with platinum-based chemotherapy and cetuximab for the first line treatment of recurrent/metastatic HNSCC were recruited. Presence of rash, hypomagnesemia, hypopotassemia, anemia, neutropenia, thrombocytopenia during treatment and treatment response, date of progression, date of last visit and death were recorded. Results A total of 138 patients' data were available for analysis. Any grade of rash was detected in 57 (44.5%) of the patients. The incidence of rash was significantly higher in patients with objective response than in patients with disease progression (%56.8 vs %14.3, p < 0.001). Progression free survival was 7.06 months (4.98-9.15) in patients treated with cetuximab and chemotherapy as first line treatment. In the multivariate analysis; rash was significantly correlated with longer PFS (HR 2.136; 95% CI 1.067-4.278; p = 0.032). Progression free survival was 9.65 months in patients who experienced rash, and 6.02 months in patients without rash, (p = 0.019, log-rank test). Overall survival was 11.24 months (9.65-12.82). In multivariate analysis, the survival of patients with rash was significantly longer than patients without rash (HR 1.954; 95% CI 1.162-3.285; p = 0.012). Overall survival was 15.08 months in patients who experienced rash, and 8.61 months in patients without rash (p = 0.05, log-rank test). Conclusion Cetuximab-induced rash is associated with better ORR and longer PFS and OS in patients with recurrent/metastatic HNSCC treated with Cetuximab and platinum-based chemotherapy.
dc.identifier.citationSezgin Göksu, S., Tatlı, A. M., Geredeli, Ç., Atçı, M., Beşen, A. A., Mertsoylu, H. ... Coşkun, H. Ş. (2021). Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck. Cancer Chemotherapy and Pharmacology, 88(5), 805-812. https://dx.doi.org/10.1007/s00280-021-04328-9
dc.identifier.doi10.1007/s00280-021-04328-9
dc.identifier.endpage812
dc.identifier.issn0344-5704
dc.identifier.issn1432-0843
dc.identifier.issue5
dc.identifier.scopusqualityQ1
dc.identifier.startpage805
dc.identifier.urihttps://dx.doi.org/10.1007/s00280-021-04328-9
dc.identifier.urihttps://hdl.handle.net/20.500.12511/8517
dc.identifier.volume88
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofCancer Chemotherapy and Pharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectCetuximab
dc.subjectHead and Neck
dc.subjectRash
dc.titleCetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Aydin-Sabin-2021.pdf
Boyut:
681.84 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu